Usefulness of Lidocaine as Topical Pharyngeal Anaesthesia in Esophagogastroduodenoscopy Under Sedation With Propofol

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Felipe de la Morena Lopez MD, Hospital Universitario Infanta Cristina
ClinicalTrials.gov Identifier:
NCT01489891
First received: December 3, 2011
Last updated: March 7, 2013
Last verified: March 2013

December 3, 2011
March 7, 2013
December 2011
July 2012   (final data collection date for primary outcome measure)
Rate of Administration of Propofol 1% Required to Obtain Uniform Sedation During Endoscopy [ Time Frame: 8 months ] [ Designated as safety issue: No ]
The propofol will be administered by an expert anaesthetist in repeated bolus (10-20 mg each 30-60 seconds) after an initial induction dosage (0.5-0.6 mg/kg ASA (American Society of Anaesthesiologists) I-II or 0.25-0.35 mg/kg ASA III-IV) to obtain an uniform level of sedation (OAAS 3 and bispectral index (BIS) 70-80) and adequate perceived patient tolerance (no gag-reflex, cough, sudden movements).
Dosage of propofol 1% administered during endoscopy (milligrams) [ Time Frame: 8 months ] [ Designated as safety issue: No ]
The propofol will be administered by an expert anaesthetist in repeted bolus (10-20 mg each 30-60 seconds) after an initial induction dosage (0,5-0,6 mg/kg ASA I-II or 0,25-0,35 mg/kg ASA III-IV) to obtain an uniform level of sedation (OAAS 3 and BIS 75-85) and adequate perceived patient tolerance (no gag-reflex, cough, sudden movements).
Complete list of historical versions of study NCT01489891 on ClinicalTrials.gov Archive Site
  • Percentage of Participants With Adverse Events in Both Groups [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 2 hours postprocedure ] [ Designated as safety issue: Yes ]
    Hypoxemia (SatO2<90% or >4% if the baseline was under 93%), bradycardia (<60 bpm or >10% from baseline), hypotension (systolic blood pressure under 90 mmHg and/or diastolic 60 mmHg), anaphylactic reaction, aspiration o methaemoglobinemia.
  • Likert Four Elements Scale to Evaluate the Satisfaction of Endoscopist [ Time Frame: 8 months ] [ Designated as safety issue: No ]
    Define as easiness to reach the expected objectives for endoscopy without patient interference: very satisfied, satisfied, neutral, unsatisfied.
  • Likert Four Elements Scale to Evaluate the Satisfaction of Anaesthetist [ Time Frame: 8 months ] [ Designated as safety issue: No ]
    Define as easiness to reach and maintain the level of sedation and patient comfort during endoscopy: very satisfied, satisfied, neutral, unsatisfied.
  • Number of participants with adverse events in both groups [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 2 hours postprocedure ] [ Designated as safety issue: Yes ]
    Hypoxemia (SatO2<90% or >4% if the baseline was under 93%), bradycardia (<60 bpm or >10% from baseline), hypotension (systolic blood preasure under 90 mmHg and/or dyastolic 60 mmHg), anaphylactic reaction, aspiration o methaemoglobinemia.
  • Likert four elements Scale to evaluate the satisfaction of endoscopist [ Time Frame: 8 months ] [ Designated as safety issue: No ]
    Define as easiness to reach the expected objetives for endoscopy without patient interference: very satisfied, satisfied, neutral, unsatisfied.
  • Likert four elements Scale to evaluate the satisfaction of anaesthetist [ Time Frame: 8 months ] [ Designated as safety issue: No ]
    Define as easiness to reach and maintain the level of sedation and patient comfort during endoscopy: very satisfied, satisfied, neutral, unsatisfied.
Not Provided
Not Provided
 
Usefulness of Lidocaine as Topical Pharyngeal Anaesthesia in Esophagogastroduodenoscopy Under Sedation With Propofol
Usefulness of Applying Lidocaine as Topical Pharyngeal Anaesthesia in Esophagogastroduodenoscopies Performed Under Sedation With Propofol- a Randomized Controlled Trial

The purpose of this study is to determine the efficacy of application of the anaesthesia topical pharyngeal with lidocaine in esophagogastroduodenoscopy under propofol´s sedation, in therms of dosage and side effect´s reduction overall.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention
Esophagogastroduodenoscopy
  • Drug: Lidocaine
    Applying of 5 puff controlled released (50 mg) transoral spray of lidocaine (10 mg=1 puff).
  • Drug: Placebo
    Applying of 5 puff controlled released (50 mg) transoral spray of placebo (excipients of trade mark of lidocaine ensuring the patient masking).
  • Active Comparator: Lidocaine group
    Blinded spraying 50 mg of pharyngeal topical lidocaine 180 seconds before sedated esophagogastroduodenoscopy (EGD)
    Intervention: Drug: Lidocaine
  • Placebo Comparator: Placebo
    Excipients without lidocaine. The flavour taste is the same of active comparator ensuring the masking.
    Intervention: Drug: Placebo

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
120
August 2012
July 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient´s over 18 years old that received standard indication for sedated esophagogastroduodenoscopy (American Society of Gastrointestinal Endoscopy Guidelines) in our centre between the period of study.

Exclusion Criteria:

  • Patients under 18 years old
  • Unable to obtain inform´s consent
  • Emergency endoscopy
  • Pregnant women
  • Encephalopathy
  • Well known allergic reaction to propofol, amide-anaesthesics, soy or eggs
  • Methaemoglobinemia induced factor risks
  • No previous or unknown fasting
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Spain
 
NCT01489891
2011-005704-15, ATF-EGD001
Yes
Felipe de la Morena Lopez MD, Hospital Universitario Infanta Cristina
Hospital Universitario Infanta Cristina
Not Provided
Principal Investigator: Felipe de la Morena, M.D.
Hospital Universitario Infanta Cristina
March 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP